Complement-Based Drug Development Summit leaderboard
  • Tuesday, October 6, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

17th World ADC San Diego Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 21

Antares, Novartis Partner on Cancer Drug Discovery

Jun 26, 2026
Antares Therapeutics has entered into a strategic collaboration with Novartis to discover, develop, and commercialize a new generation of small-molecule cancer therapies targeting…
Read More...

FDA Approves TRYNGOLZA for Severe Hypertriglyceridemia

Jun 26, 2026
Ionis Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for TRYNGOLZA (olezarsen), a first-of-its-kind therapy designed to reduce triglyceride levels and…
Read More...

RQ Bio Raises $115 Million for Influenza Antibody Therapy

Jun 26, 2026
RQ Bio has secured $115 million (£85.5 million) in an oversubscribed Series A financing, providing the biotechnology company with significant resources to advance the clinical…
Read More...

EU Approves KEYTRUDA-Padcev for Bladder Cancer

Jun 26, 2026
Merck has secured European Union approval for a new perioperative treatment regimen combining KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) for adults with resectable…
Read More...

Merck to Acquire Bio-Techne in $11.3 Billion Deal

Jun 26, 2026
Merck KGaA, Darmstadt, Germany, has announced a definitive agreement to acquire U.S.-based life sciences company Bio-Techne Corporation in an all-cash transaction valued at…
Read More...

Ionis, Recordati Partner to Expand Zilganersen Access Globally

Jun 26, 2026
Ionis Partners with Recordati to Commercialize Alexander Disease Therapy Outside U.S. Ionis Pharmaceuticals has entered into a strategic licensing agreement with Recordati to expand…
Read More...

Remix Therapeutics to Merge With Passage Bio

Jun 25, 2026
Remix Therapeutics and Passage Bio have agreed to merge in an all-stock transaction, creating a combined biotechnology company focused on advancing RNA-targeted therapies for cancer and…
Read More...

Oura, LillyDirect Partner to Support GLP-1 Patients

Jun 25, 2026
ŌURA and LillyDirect have announced a new collaboration aimed at helping people using GLP-1 weight management medicines better manage their health through wearable technology and…
Read More...

Lilly Completes Centessa Acquisition to Advance Narcolepsy Treatments

Jun 24, 2026
Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals plc, strengthening its neuroscience pipeline with promising therapies aimed at treating narcolepsy and…
Read More...

Bayer Partners With Iambic to Accelerate AI Drug Discovery

Jun 24, 2026
Bayer has entered into a strategic drug discovery collaboration with Iambic Therapeutics to accelerate the development of new small-molecule medicines using artificial intelligence. The…
Read More...
Previous 1 … 19 20 21 22 23 … 956 Next
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Microbiome Movement USA Summit 2026
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Biomarker Operations & Biospecimen Management
2nd Obesity & Weight Loss Drug Development Summit Europe
RNA-Based Therapeutics & Vaccines Summit South Korea
RNA-Targeted Drug Discovery & Development Summit
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
10th IPF Summit
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
17th World ADC London
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Model-Informed Drug Development Summit 2026
IMPACCT Real-World Evidence Summit
Raw Materials for Cell & Gene Therapy Summit
10th Dermatology Drug Development Summit
9th Lab Asset & Facility Management Summit
Covalent Drug Discovery & Development Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
17th World ADC San Diego
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Sanofi, Regeneron Expand Antibody Collaboration With $8B Deal
  • Abogen, Novartis Sign $7.2B RNA Therapeutics Deal
  • CAS, Novartis Partner on AI-Ready Reaction Data for Drug Discovery
  • SK pharmteco Invests $200M to Expand U.S. Drug Manufacturing
  • AstraZeneca Invests $2B in Summit Therapeutics for Cancer Research

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Direct RNA Binding Emerges as a Powerful Approach for…

AI, Structure Prediction and Advanced Computational Tools…

New Preclinical Data and Translational Advances Set to Take…

FDA, Health Canada & Leading Biopharma Organizations…

Industry Leaders Convene in Boston as Registration Remains…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.